Curiox BioSystems
Financials
Valuation Metrics
Curiox BioSystems's Market Cap is ₩9129B. At end of 2025 it was ₩2.0T. Ranked #315 of 2,410 in KR market (top 13%), #89 of 1,631 on KOSDAQ (top 5%), #34 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 912.91B KRW | KR#315/2,410 Sec#34/231 |
| Revenue | 5.73B KRW | KR#2,320/2,410 Sec#189/231 |
| Net Income | -12.78B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 53.33B KRW | KR#2,177/2,410 Sec#196/231 |
| Net Assets | 48.99B KRW | KR#1,916/2,410 Sec#160/231 |
| Employees | 23 | KR#2,229/2,410 Sec#210/231 |
| Value | ||
| P/B | 18.60x | KR#2,392/2,410 Sec#224/231 |
| P/S | 158.90x | KR#2,386/2,410 Sec#214/231 |
| FCF Yield | -1.23% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -26.09% | KR#2,138/2,410 Sec#167/231 |
| ROA | -23.96% | KR#2,265/2,410 Sec#185/231 |
| Op. Margin | -227.43% | KR#2,327/2,410 Sec#187/231 |
| Revenue Growth | 49.92% | KR#209/2,410 Sec#29/231 |
| Financial Health | ||
| Debt Ratio | 8.87% | KR#118/2,410 Sec#25/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | -11.25B KRW | KR#1,737/2,410 Sec#156/231 |
| Cash | 10.50B KRW | KR#1,663/2,410 Sec#141/231 |
| Current Ratio | 5.24x | KR#264/2,410 Sec#49/231 |
| Performance | ||
| 1Y Return | -30.12% | KR#1,415/2,410 Sec#106/231 |
| 1M Return | -9.11% | KR#1,593/2,410 Sec#158/231 |
| From 52W High | -64.54% | KR#1,946/2,410 Sec#164/231 |
| 1Y MDD | -75.43% | KR#2,160/2,410 Sec#189/231 |
| Trading | ||
| Volume | 120,090 shares | KR#172/2,410 Sec#9/231 |
| Trading Value | 6.46B KRW | KR#105/2,410 Sec#5/231 |
| Foreign Own. | 7.03% | KR#635/2,410 Sec#56/231 |
| Per Share | ||
| EPS | -742 KRW | KR—/2,410 Sec—/231 |
| BPS | 2,844 KRW | KR#1,904/2,410 Sec#146/231 |
Company Info
Curiox Biosystems was established in 2018 to commercialize cell analysis process automation technology, developing a global sales network via subsidiaries in the United States, China, and Singapore. The company sells automated cell pre-processing equipment, plates, and accessories, featuring its unique Curiox C-FREE™ technology that significantly improves automation, data accuracy, and reproducibility in cell analysis. This non-centrifuge-based automated cell pre-processing product grants it a distinctive market position. Curiox Biosystems is headquartered in Geumcheon-gu, Seoul Metropolitan City.